PT - JOURNAL ARTICLE ED - , TI - â–¼Pioglitazone and â–¼rosiglitazone for diabetes AID - 10.1136/dtb.2001.39965 DP - 2001 Sep 01 TA - Drug and Therapeutics Bulletin PG - 65--68 VI - 39 IP - 9 4099 - http://dtb.bmj.com/content/39/9/65.short 4100 - http://dtb.bmj.com/content/39/9/65.full SO - Drug Ther Bull2001 Sep 01; 39 AB - Relevant BNF section: 6.1.2.3&#9660Pioglitazone* (Actos - Takeda) and &#9660rosiglitazone* (Avandia - GlaxoSmithKline) belong to a new class of oral antidiabetic medicines (the glitazones or thiazolidinediones). Both are licensed in the UK for "oral combination treatment of type 2 diabetes mellitus in [narrowly defined groups of] patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin or a sulphonylurea". They are not licensed for use as monotherapy, in combination with insulin, or as part of triple therapy with metformin or a sulphonylurea. What can pioglitazone and rosiglitazone offer in the management of patients with type 2 diabetes?